Encouraging Trends in Peanut Allergy Prevention: Real-World Impact of Prevention Guidelines

In this issue of Pediatrics, Gabryszewski et al1 provide evidence that efforts to prevent peanut allergy at the population level may be beginning to take hold in the United States. Their analysis, based on electronic health record (EHR) data in the American Academy of Pediatrics (AAP) Collaborative Electronic Reporting database, demonstrates a decline in the incidence of peanut allergy among children born after the publication of the Learning Early About Peanut Allergy (LEAP) trial findings in 2015.2 This is one of the first reports suggesting that clinical research findings and subsequent guidelines on early allergen introduction may be translating into meaningful real-world impact.Food allergy prevalence has been on the rise, with 8% of children in the United States having food allergy and 2.2% having peanut allergy.3 However, over the past decade, a paradigm shift has occurred in pediatric food allergy prevention. Early introduction of allergenic foods, especially peanuts, while once discouraged, has become a cornerstone recommendation following findings of the LEAP trial, which demonstrated that introducing peanut products in infancy significantly reduced the relative risk of peanut allergy among children at high risk of developing peanut allergy.2 These results triggered interim guidance in August 20154 and the subsequent release of the 2017 National Institute of Allergy and Infectious Diseases (NIAID)-sponsored Addendum Guidelines for the Prevention of Peanut Allergy in the United States,5 which was endorsed by multiple organizations, including the AAP. The Addendum Guidelines formally recommended early peanut introduction for all infants at low risk of developing peanut allergy (no/mild/moderate eczema) and for high-risk infants (severe eczema and/or egg allergy) if appropriate after testing for peanut allergy.Despite these advances, implementation of recommendations in practice has faced challenges. A survey of pediatricians in the years following the release of the 2017 guidelines indicated confusion, lack of confidence, and uncertainty around how to operationalize early peanut introduction.6 Moreover, some have questioned whether these recommendations would be effective outside of tightly controlled clinical settings because a population-based study in Australia found no significant overall reduction in peanut allergy prevalence despite widespread awareness of the benefits of early peanut introduction.7It is against this backdrop that the data presented by Gabryszewski et al are encouraging. The authors report a 27.2% reduction in the cumulative incidence of peanut allergy among children in the post–initial guidelines cohort vs the preguidelines cohort.1 An even larger reduction was observed when the preguidelines cohort was compared with the post–addendum guidelines cohort. These findings suggest a possible shift in food allergy epidemiology that aligns temporally with both LEAP and the subsequent guideline dissemination. Particularly noteworthy is the associated decline in parent-reported peanut allergy diagnoses in the National Health Interview Survey, a sign that awareness and practice patterns may be changing.8The authors are to be commended for leveraging data from the AAP's harmonized EHR database. This resource represents a significant step forward in capturing real-time, practice-based trends in food allergy prevalence. However, caution is warranted in interpreting these findings. The data were collected from a subset of participating practice sites (both independently owned and affiliated with academic health systems) and may not be fully representative of the broader US pediatric population. Future analyses should seek to validate these trends in larger, more diverse samples using expanded diagnostic criteria, such as food allergy testing and oral food challenges.Several additional considerations arise. First, it is somewhat surprising to observe a decrease in food allergy prevalence so soon after the LEAP publication. Given that the LEAP trial findings themselves were not a guideline and that the 2017 Addendum Guidelines followed 2 years later, the immediacy of this trend raises questions about other contributing factors. Specifically, the study also identified decreases in milk allergy incidence, but not in egg allergy, despite the guidelines' primary focus on peanut. This discrepancy suggests a potential spillover effect, in which broader shifts in pediatric dietary practices or diagnostic approaches may be influencing trends in food allergy more generally.Finally, the potential role of improved diagnostic clarity should not be overlooked. The 2010 NIAID guidelines on food allergy diagnosis9 may have influenced provider behavior in ways that contributed to more accurate identification of true immunoglobulin E–mediated food allergy, possibly reducing overdiagnosis in subsequent years.In summary, the findings by Gabryszewski et al offer promising evidence that early allergen introduction is not only being adopted but may be making a measurable impact. These trends merit further investigation, including exploration of variation in implementation and effects across sociodemographic groups. If confirmed, these findings would represent a meaningful public health advance—affirming that clinical research, when coupled with clear guidelines and committed dissemination, can indeed shift the trajectory of childhood food allergy.